Contact information Verified work emails, personal emails, and direct dials — unlocked in one click.
Work email
•••••@msnlabs.com
Personal email
•••••@•••••.com
Direct dial
+•• ••• ••• ••••
Free to start · No credit card required
Current company MSN Laboratories
Pharmaceutical Manufacturing · 9.7K employees
MSN Group is one of the fastest-growing, research-based and fully integrated pharmaceutical companies based out of Hyderabad, India. It was founded in the year 2003 with a mission to make high-quality medicines affordable and accessible to the world. The organization presently has 25 state-of-the-art manufacturing facilities (17 API and 8 Finished Dosage Facilities) established in India and USA.
The group has an integrated R&D centre that facilitates the research of both API and Finished Dosages under one roof, enabling the organization to introduce new and affordable therapies in global markets swiftly. Backed by a dedicated and experienced team of over 15,000 qualified professionals, the organization has earned a global distinction for its innovation, quality and speed of delivery besides achieving the following:
> About 900+ national and international patent applications filed
> Product portfolio of 500 + APIs & 400+ Finished Dosages
> Over 35 major therapeutic offerings covering Oncology, Cardiology, CNS, Diabetes, Nephrology, Urology, Gastroenterology, Orthopaedics etc.
> World No. 1 in active US DMF Filings
> Won the trust of more than 40 Million patients across 100+ countries
The organizational environment at MSN Labs integrates multiple disciplines and functions by effective implementation of goals and objectives through technology coupled with Integrity, Imagination and Innovation. The company’s proactive marketing, robust IP strategy, innovative R&D expertise, dynamic SCM, Insight-driven IT, and world-class facilities remain at the heart of its continuing success.
We own a track record of growing at an exponential pace since our inception. From 22 Million USD in 2005 to achieving over 1 billion USD turnover in FY 2024-25 and counting, we continue to expand our growth and global footprint by creating innovative solutions for tomorrow's healthcare requirements.